JP5860398B2 - 視覚サイクルモジュレーターの薬理 - Google Patents

視覚サイクルモジュレーターの薬理 Download PDF

Info

Publication number
JP5860398B2
JP5860398B2 JP2012519634A JP2012519634A JP5860398B2 JP 5860398 B2 JP5860398 B2 JP 5860398B2 JP 2012519634 A JP2012519634 A JP 2012519634A JP 2012519634 A JP2012519634 A JP 2012519634A JP 5860398 B2 JP5860398 B2 JP 5860398B2
Authority
JP
Japan
Prior art keywords
hours
compound
administration
alkyl
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012519634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532197A5 (enExample
JP2012532197A (ja
Inventor
良 窪田
良 窪田
ボーマン、ナンシー
バビック、クレス
スコット、イアン、エル
Original Assignee
アキュセラ インコーポレイテッド
アキュセラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アキュセラ インコーポレイテッド, アキュセラ インコーポレイテッド filed Critical アキュセラ インコーポレイテッド
Publication of JP2012532197A publication Critical patent/JP2012532197A/ja
Publication of JP2012532197A5 publication Critical patent/JP2012532197A5/ja
Application granted granted Critical
Publication of JP5860398B2 publication Critical patent/JP5860398B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012519634A 2009-07-02 2010-07-02 視覚サイクルモジュレーターの薬理 Active JP5860398B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22287509P 2009-07-02 2009-07-02
US61/222,875 2009-07-02
US26692209P 2009-12-04 2009-12-04
US61/266,922 2009-12-04
PCT/US2010/040983 WO2011003103A2 (en) 2009-07-02 2010-07-02 Pharmacology of visual cycle modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015247328A Division JP6118886B2 (ja) 2009-07-02 2015-12-18 視覚サイクルモジュレーターの薬理

Publications (3)

Publication Number Publication Date
JP2012532197A JP2012532197A (ja) 2012-12-13
JP2012532197A5 JP2012532197A5 (enExample) 2013-08-22
JP5860398B2 true JP5860398B2 (ja) 2016-02-16

Family

ID=43411786

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012519634A Active JP5860398B2 (ja) 2009-07-02 2010-07-02 視覚サイクルモジュレーターの薬理
JP2015247328A Active JP6118886B2 (ja) 2009-07-02 2015-12-18 視覚サイクルモジュレーターの薬理

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015247328A Active JP6118886B2 (ja) 2009-07-02 2015-12-18 視覚サイクルモジュレーターの薬理

Country Status (5)

Country Link
US (3) US10471027B2 (enExample)
EP (2) EP4000610A1 (enExample)
JP (2) JP5860398B2 (enExample)
ES (1) ES2897527T3 (enExample)
WO (1) WO2011003103A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104768A (ja) * 2009-07-02 2016-06-09 アキュセラ インコーポレイテッド 視覚サイクルモジュレーターの薬理

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2541430C2 (ru) 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
HK1210969A1 (en) * 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
CA2903483A1 (en) 2013-03-12 2014-10-09 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH380746A (de) 1958-11-06 1964-08-15 Ciba Geigy Verfahren zur Herstellung neuer sekundärer Amine
GB884663A (en) 1958-11-06 1961-12-13 Ciba Ltd New amines and processes for their manufacture
CH396941A (de) 1959-08-10 1965-08-15 Ciba Geigy Verfahren zur Herstellung neuer sekundärer Amine
GB1145278A (en) 1964-07-07 1969-03-12 Wellcome Found Amidine derivatives, processes for their preparation, and compositions incorporating them
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
JPS50112386A (enExample) 1974-02-27 1975-09-03
DE2710997C3 (de) 1977-03-14 1980-08-14 Dr. Karl Thomae Gmbh, 7950 Biberach 4-Alkoxy carbonylamino-phenyläthanolamine, deren Herstellung und deren Verwendung als Arzneimittel
JPS6025958A (ja) 1983-07-21 1985-02-08 Kowa Co 新規アミノアルキル置換ベンゼン誘導体
JPH0228112A (ja) * 1988-04-21 1990-01-30 Kaken Pharmaceut Co Ltd 点眼用眼圧調整剤
US5135955A (en) 1988-04-25 1992-08-04 Eli Lilly And Company Propanamine derivatives
IT1240427B (it) 1990-03-02 1993-12-15 Ministero Dall Uni E Della Ric Arilpropilammine ad azione antifungina
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69224861T2 (de) 1991-07-30 1998-08-06 Korea Res Inst Chem Tech Neue Phenylacetamidderivate und Verfahren zu ihrer Herstellung
WO1993015045A1 (en) 1992-01-29 1993-08-05 Smithkline Beecham Corporation N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
CA2181581A1 (en) 1994-01-19 1995-07-20 Jan Bron Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JP2007008957A (ja) 1994-08-22 2007-01-18 Mitsubishi Pharma Corp ベンゼン化合物およびその医薬としての用途
US5541228A (en) 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
CA2159759A1 (en) 1994-10-14 1996-04-15 Katherine S. Takaki Melatonergic agents
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
AU723349B2 (en) 1996-06-07 2000-08-24 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE19643592A1 (de) 1996-10-22 1998-04-23 Bayer Ag Verfahren zur Herstellung von alpha-Alkoxy-alpha-trifluormethyl-arylessigsäureestern und -arylessigsäuren
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6051605A (en) 1997-08-08 2000-04-18 Warner-Lambert Company Method of treating psychosis and schizophrenia
EP1020441A4 (en) 1997-09-11 2002-02-20 Kureha Chemical Ind Co Ltd N-HETEROCYCLIC METHYL PROPYLAMINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND GERMIZIDE
US6171837B1 (en) 1997-09-29 2001-01-09 The Trustees Of Columbia University In The City Of New York Mouse and human 9-cis-retinol dehydrogenase
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
JP2001031636A (ja) 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd α−ケトアミド誘導体およびその医薬用途
CA2393466C (en) 1999-12-21 2010-01-19 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
JP2003342261A (ja) 2000-05-09 2003-12-03 Kureha Chem Ind Co Ltd Ｎ−ヘテロ環メチル−アルキルアミン誘導体、その製造方法、および殺菌剤
MXPA02011921A (es) 2000-05-30 2003-04-22 Guilford Pharm Inc Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
DE10235312A1 (de) 2002-08-01 2004-02-12 Basf Ag Verfahren zur Herstellung von Aminoalkoxybenzylaminen und Aminoalkoxybenzonitrilen als Zwischenprodukte
WO2004082622A2 (en) 2003-03-14 2004-09-30 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
KR20110140139A (ko) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
KR20070011379A (ko) * 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
WO2006091796A2 (en) 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2006105215A2 (en) 2005-03-28 2006-10-05 Acucela, Inc. The use of a spin trap for enhancing retinal cell survival and treating retinal degenerative diseases
TW200716110A (en) 2005-04-20 2007-05-01 Smithkline Beecham Corp Inhibitors of AKT activity
TW200744567A (en) 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
EP1973868B1 (en) 2006-01-13 2015-09-09 McGill University Novel elatonin ligands having antidepressant activity as well as sleep inducing properties
WO2007120528A2 (en) 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
RU2470910C9 (ru) * 2007-06-29 2013-05-20 Акьюсела, Инк. Соединения, представляющие собой алкинилфенильные производные, для лечения офтальмических заболеваний и расстройств
RU2541430C2 (ru) 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
EP4000610A1 (en) * 2009-07-02 2022-05-25 Acucela Inc. Pharmacology of visual cycle modulators
TW201406707A (zh) * 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104768A (ja) * 2009-07-02 2016-06-09 アキュセラ インコーポレイテッド 視覚サイクルモジュレーターの薬理

Also Published As

Publication number Publication date
US20200188336A1 (en) 2020-06-18
JP6118886B2 (ja) 2017-04-19
US10471027B2 (en) 2019-11-12
EP2448569B1 (en) 2021-10-27
ES2897527T3 (es) 2022-03-01
US20110003895A1 (en) 2011-01-06
EP4000610A1 (en) 2022-05-25
US20230270700A1 (en) 2023-08-31
WO2011003103A3 (en) 2011-05-26
EP2448569A4 (en) 2012-12-26
EP2448569A2 (en) 2012-05-09
JP2012532197A (ja) 2012-12-13
JP2016104768A (ja) 2016-06-09
WO2011003103A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
US20230270700A1 (en) Pharmacology of visual cycle modulators
KR20150013240A (ko) 당뇨병성 망막병증 및 기타 안과 질환의 치료 방법
TWI848911B (zh) 以三唑并吡啶治療rbp4相關疾病之方法
JP2023524563A (ja) Ａｐｏｌ１－関連疾患の治療に使用するための組成物
JP6903571B2 (ja) スミス‐マゲニス症候群を治療するためのタシメルテオン
JP2006523641A (ja) グルカゴンレセプターアンタゴニストとしての置換３−シアノチオフェンアセトアミド
CN107106521A (zh) 用于治疗帕金森病的新治疗方法
JP6697808B2 (ja) 感覚有毛細胞の死を防ぐまたは処置するための化合物と方法
CA3107139A1 (en) Extended release compositions comprising trihexyphenidyl
US20180000792A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
JP2022523332A (ja) 近視を治療するための化合物、組成物及び方法
ES2950453T3 (es) Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3
WO2013109991A1 (en) Substituted heterocyclic compounds for disease treatment
ES2668379T3 (es) Método para el tratamiento de trastornos del movimiento con befiradol
WO2013186311A1 (en) Extended release formulations
JP2018533631A (ja) 網膜疾患の治療のためのミラベグロン
ES2842208T3 (es) Composiciones farmacéuticas de donepezilo que tienen perfil de disolución in vitro o parámetros farmacocinéticos específicos
JP7788768B2 (ja) Ｍ－コリン受容体アゴニスト化合物及びその製造方法並びに使用
JP7506475B2 (ja) フェブキソスタット製剤
TW201035081A (en) Novel pharmaceutical composition for treatment of schizophrenia
WO2024249796A2 (en) Extended and delayed release compositions of substituted benzimidazoles
CN105748460A (zh) 一种治疗老年痴呆的药物
KR20080051246A (ko) 뇌신경계 질환의 예방 또는 치료용 및 ｎａｄｐｈ 산화효소활성억제용 약학적 조성물
JP2020189815A (ja) デュロキセチン製剤およびその安定化方法
WO2015105064A1 (ja) 網膜疾患の予防又は治療のための医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141023

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151218

R150 Certificate of patent or registration of utility model

Ref document number: 5860398

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250